Project Grant R24FD004655

CARDIOONCO-AI: Cardiotoxicity Risk Prediction Research The University of Minnesota received a Cooperative Agreement award of $2.999 million from the Food and Drug Administration (FDA) Research program (CFDA 93.103) on September 22, 2025, for the CARDIOONCO-AI project, with completion targeted for August 31, 2028. This project delivers an artificial intelligence (AI)-powered informatics framework designed to predict individualized cardiotoxicity risk among breast cancer survivors using multi-site...

Federal Cooperative Agreement Summary Yale University received a $500,000 cooperative agreement from the Food and Drug Administration's Center for Drug Evaluation and Research under the FDA Research program (CFDA 93.103), effective July 1, 2025 through June 30, 2027. The award funds development of a comprehensive Full Qualification Package (FQP) for the Positive Symptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS), a clinical outcome assessment instrument. The...

Award Summary The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center received a $249,580 Cooperative Agreement from the Food and Drug Administration's Center for Drug Evaluation and Research under the FDA Research program (CFDA 93.103), effective July 1, 2025 through June 30, 2026. The award funds analytic validation studies for Non-Calcified Plaque Volume (NCPV) assessment using Coronary CT Angiography (CCTA) imaging, with the objective of qualifying NCPV as an...

This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $1,093,825 to implement the PSYCH-DS data standard for human behavioral experiments. The key objectives are: 1) Creating validator software to ensure cross-compatibility of PSYCH-DS datasets across programming languages, 2) Integrating the PSYCH-DS standard into three popular experiment presentation software packages, and 3) Developing...

Project Grant Summary This $421,632 Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), was awarded to Vanderbilt University Medical Center on August 15, 2025, with completion targeted for April 30, 2029. The project develops a novel platform to generate partially synthetic Chemical Exchange Saturation Transfer (CEST) Magnetic...

Cooperative Agreement Summary Icahn School of Medicine at Mount Sinai received a $2.11 million Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 10, 2025, with completion targeted for April 30, 2030. The award supports the development of multimodal biometric decision-support technologies for deep brain stimulation (DBS) treatment...

Federal Project Grant Award Summary Oregon Health & Science University received a $1.29 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of May 31, 2029. The IPRISM (Imaging-Enhanced Prediction of Risk for Sudden Cardiac Death in HCM) project delivers research and analytical services focused on improving sudden cardiac death (SCD) risk...

This $717,712 Project Grant from the National Science Foundation's Division of Information and Intelligent Systems, under the Computer and Information Science and Engineering program (CFDA 47.070), will support the development and evaluation of a knowledge-enhanced and interpretable radiology report generation framework using longitudinal, multimodal electronic health record data and domain knowledge. The awardee, Joan & Sanford I Weill Medical College of Cornell University, will build a...

Summary: A Randomized Controlled Multisite Trial Evaluating SAINT for Postpartum Depression The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded Magnus Medical Inc. a Project Grant totaling $11.62 million (with a supplemental funding action of $1.61 million) to conduct a randomized controlled multisite clinical trial evaluating SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) as a treatment for postpartum...

This $1,336,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports the development of a rapid, motion-robust, and low-gadolinium MRI technology for pediatric brain tumors. The key objectives are to (1) develop cutting-edge technologies for rapid, motion-robust, and quantitative MRI scans to reduce sedation needs...